首页|1例海曲泊帕治疗儿童慢性原发性免疫性血小板减少症的案例分析

1例海曲泊帕治疗儿童慢性原发性免疫性血小板减少症的案例分析

扫码查看
临床医生和临床药师为1 例慢性原发性免疫性血小板减少症患儿制定海曲泊帕治疗方案和监测目标,随后开展的药学监护.通过20 +周的海曲泊帕治疗,患儿血小板达到并维持在目标范围,停药14 周后血小板仍可保持在正常范围.用药期间未见明显药物不良反应.为海曲泊帕治疗儿童慢性原发性免疫性血小板减少症的临床应用实践提供了一定参考.
A Case Study of Chronic Immune Thrombocytopenia in Children Treated with Hetrombopag
The clinicians and clinical pharmacists developed a treatment regimen and monitoring goals for hetrom-bopog for a child with chronic immune thrombocytopenia,followed by pharmacological care by a clinical pharma-cist.The child's platelets were achieved and maintained in the target range through 20 +weeks of hetrombopog thera-py,and platelets remained in the normal range 14 weeks after discontinuation of the drug.No significant adverse drug reactions were observed during the medication period.It provides a reference for the clinical application practice of hetrombopog in the treatment of chronic immune thrombocytopenia in children.

PediatricChronic immune thrombocytopeniaHetrombopog

蔡泽政、梁凤玲、刘洁、廖倩倩

展开 >

贵州省黔东南苗族侗族自治州人民医院药剂科,贵州凯里 556000

贵州省黔东南苗族侗族自治州人民医院儿科,贵州凯里 556000

重庆大学附属江津医院药剂科,重庆 402260

桂林市人民医院药学部,广西桂林 541000

展开 >

儿童 慢性原发性免疫性血小板减少症 海曲泊帕

2024

海峡药学
中国药学会福建分会

海峡药学

影响因子:0.643
ISSN:1006-3765
年,卷(期):2024.36(2)
  • 10